| Group Aa (n = 17) | Group Ba (n = 34) | ||
Characteristic | Anti-Nedd5 C-ter IgG (n = 8) | No anti-Nedd5 C-ter IgG (n = 9) | Anti-Nedd5 C-ter IgG (n = 6) | No anti-Nedd5 C-ter IgG (n = 28) |
Age (y), mean (range) | 38.6 (26–52) | 37.1 (23–50) | 34.5 (28–48) | 37.2 (14–70) |
Sex (males/females) | 1/7 | 2/7 | 1/5 | 3/25 |
Disease duration (y), mean (range) | 11.2 (7–21) | 6.8 (0.5–19) | 9 (5–15) | 12.1 (0.5–24) |
Arthritis, no. (%) | 5 (62.5) | 9 (100) | 5 (83.3) | 18 (64.2) |
Neurological involvement, no. (%) | 2 (25) | 4 (44.4) | 2 (33.3) | 11 (39.2) |
Renal involvement, no. (%) | 3 (37.5) | 0 | 3 (50) | 9 (32.1) |
Cytopenia, no. (%) | 5 (62.5) | 7 (77.7) | 4 (66.6) | 16 (57.1) |
Serositis, no. (%) | 2 (25) | 2 (22.2) | 2 (33.3) | 8 (28.5) |
SLEDAI >3, no. (%) | 5 (62.5) | 4 (44.4) | 4 (66.6) | 12 (42.8) |